Evidence map›Paper›PMID 24108812›Full record

SynthesisJournal of the National Cancer Institute2013

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Koji Oba, Xavier Paoletti, Steven Alberts, Yung-Jue Bang, Jacqueline Benedetti, Harry Bleiberg, Paul Catalano, Florian Lordick, Stefan Michiels, Satoshi Morita and 11 more

Open access · bronzeAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the National Cancer Institute, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 9 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 9 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Trial
  12. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016
    Trial
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 6 countries.

Koji ObaAffiliations of authors: Translational Research and Clinical Trial Center, Hokkaido University Hospital, Sapporo, Japan (KO); Biostatistics dpt, INSEM U900, Institut Curie, Paris, France (XP); Mayo Clinic, Rochester, MN (SA, DS); Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea (Y-JB); SWOG Statistical Center, Seattle, WA (JB); Brussels, Belgium (HB); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard School of Public Health, Boston, MA (PC); University Clinic Leipzig, University Cancer Center, Leipzig, Germany (FL); Biostatistics and Epidemiology department, Institut Gustave-Roussy, Universite Paris XI, Villejuif, France (SMi, J-PP); Department of Biostatistics, Yokohama City University, Yokohama, Japan (SMo); Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan (YO); Gastro-enterology department, University Hospital Europeen Georges Pompidou, Paris, France (PR); Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan (MS); Tokai Central Hospital, Kakumuhara, Japan (JS); Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan (KS); Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium (EVC); International Drug Development Institute, Louvain-la-Neuve, Belgium (MB, TB); I-BioStat, Hasselt University, Diepenbeek, Belgium (MB, TB).
Xavier Paoletti
Steven Alberts
Yung-Jue Bang
Jacqueline Benedetti
Harry Bleiberg
Paul Catalano
Florian Lordick
Stefan Michiels
Satoshi Morita
Yasuo Ohashi
Jean-Pierre Pignon
Philippe Rougier
Mitsuru Sasako
Junichi Sakamoto
Daniel Sargent
Kohei Shitara
Eric Van Cutsem
Marc Buyse
Tomasz Burzykowski
GASTRIC group
Institut Curie · FRDana-Farber Cancer Institute · USMayo Clinic in Arizona · USSeoul National University Hospital · KRTokai Central Hospital · JPHyogo Medical University · JPInternational Drug Development Institute (Belgium) · BELeipzig University · DENational Cancer Center Hospital East · JPThe University of Tokyo · JPUniversité Paris-Saclay · FRYokohama City University · JP

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Keith L. Knutson · 1985 to 2026
$151.3M
ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
NCI NIH HHS P30 CA015083NCI NIH HHS U10 CA021115
6 · The paper itself

Abstract

backgroundIn investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer.

methodsThe GASTRIC group initiated a meta-analysis of individual patient data collected in randomized clinical trials comparing adjuvant chemotherapy vs surgery alone for patients with curatively resected gastric cancer. Surrogacy of DFS was assessed through the correlation between the endpoints as well as through the correlation between the treatment effects on the endpoints. External validation of the prediction based on DFS was also evaluated.

resultsIndividual patient data from 14 randomized clinical trials that included a total of 3288 patients were analyzed. The rank correlation coefficient between DFS and OS was 0.974 (95% confidence interval [CI] = 0.971 to 0.976). The coefficient of determination between the treatment effects on DFS and on OS was as high as 0.964 (95% CI = 0.926 to 1.000), and the surrogate threshold effect based on adjusted regression analysis was 0.92. In external validation, the six hazard ratios for OS predicted according to DFS were in very good agreement with those actually observed for OS.

conclusionsDFS is an acceptable surrogate for OS in trials of cytotoxic agents for gastric cancer in the adjuvant setting.

Indexed as

GastrectomyAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCost-Benefit AnalysisDisease-Free SurvivalDrug Administration ScheduleHumansKaplan-Meier EstimateLinear ModelsOdds RatioRandomized Controlled Trials as TopicStomach NeoplasmsTime FactorsTreatment Outcome

Identifiers

PMID24108812
PMCPMC4202244
OpenAlexW2168202113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.